Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

INDUSTRY 6OTHER 4

Study Type

Interventional 4

Sponsor

Conditions

Myasthenia Gravis 4

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1238Docetaxel 1227Oxaliplatin 1184Capecitabine 1178Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 640Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × efgartigimod alfa × Clear all
NCT07072988 2025-09-24

OPTIMAGE

Centre Hospitalier Universitaire de Nice

Phase 4 Recruiting
50 enrolled

Myasthenia Gravis

NCT06765161 2025-07-29

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

Clinique Neuro-Outaouais

Phase 3 Recruiting
30 enrolled

Myasthenia Gravis

NCT06587867 2024-09-19

Seronegative Myasthenia Gravis - Efgartigimod IV

University Health Network, Toronto

Phase 3 Recruiting
30 enrolled

Myasthenia Gravis

NCT06221501 2024-01-24

Perioperative Efgartigimod for Thymoma and Myasthenia Gravis

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting
30 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡